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A phase II multi-center trial of pentostatin plus
cyclophosphamide with ofatumumab in older 
previously untreated chronic lymphocytic leukemia
patients  
There is a significant need to develop an efficient treat-
ment, without sacrificing efficacy, for older fit patients
with chronic lymphocytic leukemia (CLL) as fludarabine,
cyclophosphamide and rituximab (FCR) have very often
led to treatment-related toxicities, causing delay or ther-
apy discontinuation and thus precluding clinical bene-
fits.1,2
Pentostatin is better tolerated and less myelosuppres-
sive than fludarabine when used in combination with
cyclophosphamide. Several studies have investigated the
role of  pentostatin (P) and cyclophosphamide (C) as the
backbone of immunochemotherapy in CLL treatment.3-5
We designed this phase II trial (www.clinicaltrials.gov:
NCT01681563) using PC chemotherapy in combination
with the fully-human anti-CD20 monoclonal antibody
ofatumumab (O) specifically designed for untreated CLL
fit patients aged ≥65 years.
Patients were required to have a confirmed B-cell CLL
showing a progressive disease in need of treatment,6 an
Eastern Cooperative Oncology Group performance status
≤2, CIRS ≤6 and CrCl ≥70 mL/min.  Having provided
written informed consent, 47 patients, median age 72
years (range: 65-83), 68% male, were enrolled in the
study between September 2011 and May 2013 in 12
Italian centers. Responses were categorized according to
the Guidelines of the International Workshop on CLL,6
related adverse effects were graded with the use of the
NCI Common Terminology Criteria for Adverse Events
(CTCAE) version 4.03.7 In patients achieving a CR, MRD
was quantified by four-color flow cytometry on peripher-
al blood samples collected 3 months after the last course
of  treatment with a sensitivity of at least (10-4), according
to the technique previously described.8MRD results were
categorized into low levels, <10-4 corresponding to “MRD
negativity”, and high levels, ≥10-4  corresponding to “MRD
positivity”.
The regimen consisted of  intravenous pentostatin 2
mg/m2 and cyclophosphamide 600 mg/m2 on day 1 every
3 weeks for a total of 6 courses. On the first course, intra-
venous ofatumumab was administered at 300 mg on day
1 and 1000 mg on day 8. For the  subsequent cycles,
patients received ofatumumab on day 1 at the dose  of
1000 mg. During the first and second courses, ofatumum-
ab infusion reaction prophylaxis consisted of oral parac-
etamol 1000 mg, intravenous clorfenamine 10 mg and
intravenous prednisolone 50 mg. Pre-medication with
glucocorticoid could be reduced or omitted from the third
course. Anti-infective prophylaxis consisted of cotrimox-
azole 960 mg 3 times a week and acyclovir 400 mg twice
a day for up to 3 months following PCO discontinuation.
Granulocyte-colony stimulating factor (G-CSF) and ery-
thropoietin were allowed according to the physician's
discretion. The first course of treatment was adminis-
tered at full doses regardless of pre-existing cytopenias. 
Clinical and disease characteristics are shown in Table
1. Patients received a median of 6 courses of therapy
(range: 2-6), with 44 (94%) completing the intended
treatment. 3 patients discontinued treatment: 2 cases,
considered as treatment failures at the final evaluation,
received only 2 courses as they developed acute renal fail-
ure and septic shock, respectively. In one case treatment
was withheld after 5 courses due to persisting skin rash.
On an intention-to-treat analysis, ORR resulted as 89.4%
(95% CI, 80.9 % to 97.9%), with 24 (51.1%) CRs, includ-
haematologica 2015; 100:e501
LETTERS TO THE EDITOR
Table 1.  Responses after PCO according to clinical and biological characteristics.
No. OR CR CR MRD- PR SD Tx Failure
pts No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
47 42 (89.4) 24 (51.1) 19 (40.4%) 18 (38.3) 3 (6.4) 2 (4.2)
Age
≥ 70y 29 26 (89.7) 15 (51.7) 13 (44.8) 11 (37.9) 1 (3.4) 2 (6.9)
< 70y 18 16 (88.9) 9 (50) 6 (33.3) 7 (38.8) 2 (11.1) 0 (0)
Binet stage
B 35 31 (88.6) 18 (51.4) 15 (42.9) 13 (37.1) 2 (5.7) 2 (5.7)
C 12 11 (91.7) 6 (50) 4 (33.3) 5 (41.7) 1 (8.3) 0 (0)
Beta-2 microgobulin
≥ 4000 g/L 15 11 (73.3) 3 (20.0) 2 (13.3) 8 (53.3) 2 (13.3) 2 (13.3)
< 4000 g/L 32 31 (96.9) 21 (65.6) 17 (53.1) 10 (31.3) 1 (3.1) 0 (0)
Bulky Disease
Yes 6 6 (100) 2 (33.3) 2 (33.3) 4 (66.6) 0 (0) 0 (0)
No 41 36 (87.8) 22 (53.7) 17 (41.5) 14 (34.1) 3 (7.3) 2 (4.9)
IgHV
mutated 25 21 (84.0) 14 (56.0) 12 (48.0) 7 (28.0) 2 (8.0) 2 (8.0)
unmutated 22 21 (95.5) 10 (45.5) 7 (31.8) 11 (50.0) 1 (4.5) 0 (0)
FISH
13q del 17 14 (82.4) 9 (52.9) 7 (41.2) 5 (29.4) 1 (5.9) 2 (11.8)
Normal 13 13 (100) 7 (53.8) 6 (46.2) 6 (46.2) 0 (0) 0 (0)
+12 7 6 (85.7) 5 (71.4) 4 (57.1) 1 (14.3) 1 (14.3) 0 (0)
11q del 7 6 (85.7) 2 (28.6) 2 (28.6) 4 (57.1) 1 (14.3) 0 (0)
17p del 3 3 (100) 1 (33.3) 0 (0) 2 (66.7) 0 (0) 0 (0)
ing 6 CRi (12.8%), and 18 (38.3%) PRs. Responses
according to clinical and biological disease characteristics
are shown in Table 1. None of the prognostic and clinical
features considered significantly impacted on OR attain-
ment, Β2MG ≥4000 mg/L was the only characteristic
influencing the achievement of a lower CR rate
(P=0.003).
Among the 24 CR patients, 19 (79%) reached MRD
negativity. Overall 40.4% of all patients enrolled in the
study obtained a MRD negative CR status at final restag-
ing. Patients presenting with a lower B2MG level had a
trend toward a higher chance of achieving MRD negativ-
ity (54.8% versus 18.2%, P=0.06). None of the other prog-
nostic features associated with a negative MRD. 
Overall 273 PCO courses were administered, adverse
events are listed in Table 2. Neutropenia was the major
cause of treatment delay or chemotherapy dose reduc-
tion, occurring in 9.9% and 4% of courses, respectively.
G-CSF, either as prophylaxis or to treat neutropenia, was
administered for a median of 3 days (3-6) in 74 courses
(27.1%). After the last course of treatment, five patients
showed a delayed onset neutropenia lasting a median of
1 month (range: 1-9), resolving in all cases. Development
of neutropenia, treatment delay and/or discontinuation
were not influenced by age or any of the patients clinical
characteristics. 
Median PFS of all enrolled patients has not been
reached after a median follow-up of 22 months, 2-year
PFS resulted as 69% (95% CI, 50.95% to 81.33%). We
observed one treatment related death with a 2-year OS of
97.9%. 9 (21%) of the 42 responding patients progressed
after a median of 15 months (range: 9–27). In 6 of them
at least one adverse prognostic feature was recorded (6
unmutated, 3 del 17p)
The only pre-treatment feature significantly associated
with a shorter PFS was a B2MG ≥4000 mg/L (median 15
months vs. n.r. P=0.008). PFS resulted significantly longer
in patients reaching MRD negativity (P=0.008) (Figure 1).
During follow-up 2 cases developed a myelodysplastic
syndrome, following treatment completion in one case
and after 15 months in the other case. PC based
immunochemotherapy studies in treatment-naïve
patients demonstrated that these combinations are as
effective as FCR in terms of response attainment.3,5 It is
noteworthy that PCR led to a similar clinical benefit
when comparing younger to older patients (ORR 93%
versus 83%, CR 41% versus 39%). In this study we con-
firm the good tolerability and efficacy of PC in combina-
tion with ofatumumab even in an elderly CLL popula-
tion. Treatment was completed in the majority of
patients (94%) with no difference when patients were
categorized according to age. The enhanced tolerability
of the therapy is also confirmed by the low rate of treat-
ment delay (9.9% of cycles) and need for dose reduction
(4%).  FCR administration in the CLL 8 trial, in a relative-
ly young and fit population, led to a high rate (26%) of
patients not completing the intended 6 courses with dose
reductions, more than 10% in 47% of patients.1
Furthermore the MDACC study experience revealed that
early discontinuation and long-term cytopenias were sig-
nificantly associated with an age >65 years.2 The
enhanced tolerability of PCO enabled us to preserve the
dose intensity allowing for the attainment of similar
results, even in terms of CR, observed in the elderly treat-
ed with FCR both in the CLL 8 and MDACC trials.1,9
It should be emphasized that the addition of ofatu-
mumab, with its ability to promote CDC,   allowed a sig-
nificant proportion of patients to achieve not only a high
CR rate, but also a MRD negative CR. It is difficult to
compare MRD results among trials as methods, time
points and sample sources differ widely across studies. It
is well known that MRD is a key factor for durable remis-
sion and Böttcher et al. demonstrated that the profound
reduction of tumor load, regardless of treatment regimen,
represents the most important prognostic feature.10 In our
series we confirm the prognostic value of MRD level as
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Table 2. Grade 3-4 toxicity and infections.
No. episodes % on 47 pts % on 273 courses
Hematological
Neutropenia 51 53.2 18.7
Anemia 1 2.1 0.4
Thrombocytopenia 0 - -
Infusion related
Skin Rash 4 8.5 1.5
Dyspnoea 3 6.4 1.1
Fainting 1 2.1 0.4
Chills 1 2.1 0.4
Glottic Edema 1 2.1 0.4
Hypotension 1 2.1 0.4
Nausea 1 2.1 0.4
Extra-hematological
Atrial Fibrillation 1 2.1 0.4
Acute renal failure 1 2.1 0.4
FUO 20 29.8 7.3
Infections
Major 2° 4.3 0.7
Minor 4* 8.5 1.5
Hospitalization 3 6.4 1.1
°2 major infections:1 radiologically documented pneumonia; 1 fatal sepsis sustained by Pseudomonas Aeruginosa.*4 minor infections: 2 urinary tract infections; 1 upper res-
piratory tract infection; 1 cellulitis.
PFS showed a clear difference (P=0.008) when patients
were categorized according to their MRD status.
Bendamustine could represent a suitable alternative to
more intensive schedules for treatment-naïve elderly
patients, even though there are no prospective clinical tri-
als specifically addressing the role of bendamustine in
combination with anti-CD20 monoclonal antibodies in
this setting.  A subanalysis of the older population (>70
years) enrolled in a study by Fisher et al. in which ben-
damustine was administered at 90mg/m2, showed that a
low CR rate was attained (11.5%) with a significantly
higher incidence of non-hematologic toxicity when com-
pared to younger patients.11 Similarly, in a retrospective
Italian trial the same bendamustine dosage had to be
reduced in 55.7% of patients aged ≥65 years due to
hematological toxicity.12  
To ameliorate tolerability in elderly patients with coex-
isting comorbidities and/or not suitable for purine
analogs, chlorambucil-based approaches have been evalu-
ated.13,14 The addition of either rituximab, ofatumumab or
obinutuzumab to chlorambucil translates into a superior
CR rate and prolongation of PFS when compared to
monotherapy alone. Furthermore, the combination of
anti-CD20 monoclonal antibodies with chlorambucil
allowed patients to obtain a negative MRD in bone mar-
row and peripheral blood.13,14 In respect to patients
enrolled in these studies our population showed a reduced
number of comorbidities, but median age was very simi-
lar. As expected, PCO, which may be considered a more
intensive treatment, led to a better quality of responses
and allowed for the attainment of higher MRD negative
CRs, resulting in a better clinical outcome. Notably, this
more intensive treatment did not exert an increased inci-
dence of infections or grade 3-4 neutropenia.  
Inhibitors of kinases downstream of the B-cell receptor
and the selective B-cell lymphoma antagonist represent a
novel class of drugs whose mechanisms of action are dif-
ferent from traditional cytotoxic agents and antibodies.
Emerging data on these therapies, showing impressive
results on relapsed/refractory CLL and their ability to
overcome the negative impact of adverse prognostic fac-
tors, challenge the standard front-line treatment.15
Moreover, the low degree of myelosuppression reported
along with the low levels of non-hematological toxicities,
make these agents useful, primarily in elderly patients. In
seeking to eliminate chemotherapy from the initial treat-
ment approach, a number of studies are continuing to
combine them with other non-cytotoxic agents.
However, the clinical advantage of these combinations
needs to be consistently proven because of the relevant
economic consequences that might preclude  the overall
sustainability of such treatments.
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